New Procedures are Bound to Modify Our Attitude in Facing Urologic Cancers in the Near Future: Are We Ready for a Cost-Effectiveness Analysis?

European Urology

Volumn 52, Issue 1, 2007, Pages 11-14

  Colombo, Renzo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; AMINOLEVULINIC ACID HEXYL ESTER; ESTER;

ATTITUDE TO HEALTH; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER RELAPSE; COST EFFECTIVENESS ANALYSIS; CYSTECTOMY; CYSTOSCOPY; ECONOMIC ASPECT; EDITORIAL; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINARY TRACT CANCER;

COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES, UROLOGICAL; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; UROLOGIC NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 34248998136     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.043     Document Type: Editorial

References (10)

1. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost effective in long-term application? A Germany-based cost analysis. Eur Urol 52 (2007) 142-147
2. Kriegmair M., Zaak D., Rothenberger K.H., et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168 (2002) 475-478
3. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
4. Neymark N., and Torfs K. Economics of urinary tract cancers: state of the art. Eur Urol 31 suppl 1 (1997) 72-81
5. Riley G.F., Potosky A.L., Lubitz J.D., and Kessler L.G. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33 (1995) 828-841
6. Sangar V.K., Ragavan N., Matanhelia S.S., Watson M.W., and Blades R.A. The economic consequences of prostate and bladder cancer in the UK. BJU Int 95 (2005) 59-63
7. Hedelin H., Holmang S., and Wiman L. The cost of bladder tumor treatment and follow-up. Scand J Urol Nephrol 36 (2002) 344-347
8. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., Marberger M., and Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
9. Avritscher E.B., Cooksley C.D., Grossman H.B., et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68 (2006) 549-553
10. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., Nativ O., Sidi A., Leib Z., Colombo R., Naspro R., Pavone-Macaluso M., Baniel J., Hasner F., and Witjes J.A. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46 (2004) 65-72